Document is current
Any future updates will be listed below
-
Authors
Oommen, Anu Mary https://orcid.org/0000-0003-2932-7827
Ashfaq, Maleeha
Ranjani, D. Priya
Suresh, Dhayanidhy
Paul, John
Ebenezer, Nirmal
Malini, Tabeetha
Mukherjee, Pavan Kumar
Singarayar, Pravin
Prakash, Praveen
Nightingale, Claire
Brotherton, Julia
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (APP2009317)
- License Information
-
More Information
Article History
Received: 17 September 2025
Accepted: 20 October 2025
First Online: 17 January 2026
Declarations
:
: JB was previously employed by the Australian Centre for the Prevention of Cervical Cancer (ACPCC), which has received funding for commercial HPV test validation projects from Abbott, AusDiagnostics, Cepheid, Copan, Roche, Seegene, Teal Health, and V-Veil. ACPCC has also received equipment of supplies from Abbott, AusDiagnostics, BD, Cepheid, Copan, Hologic, MicroBix, NRL, Qiagen, Rovers, Roche and Seegene for research purposes. All authors are part of the SHE-CAN trial for which consumables have been donated by Copan, Abbott, and Seegene, while Cepheid provided special pricing for its products through its Global Access Program. Liger India provided special introductory pricing for the IRIS thermocoagulator with digital colposcope. The sponsors had no role in the design, conduct or reporting of this study.
: The study received approval from the Institutional Review Board and Ethics Committee of the Christian Medical College Vellore (14314 INTERVEN), the Institutional Ethics Committee, Salem Polyclinic (SPCIEC/2022/Jun1/01/02), the Alfred Hospital Ethics Committee (HREC Ref 80134, Local Reference: project 601/21), Melbourne, Australia, and the IARC Ethics Committee (IEC 21-32), Lyon, France. The study was conducted following the principles of the Declaration of Helsinki. All participants provided written informed consent to participate in the study. Analysis was done using anonymized transcripts.
